Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

For the last two decades, pathogenic concepts in Parkinson disease (PD) have revolved
around the toxicity and spread of α-synuclein. Thus, α-synuclein would follow caudo-rostral …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

The central cholinergic system includes the basal forebrain nuclei, mainly projecting to the
cortex, the mesopontine tegmental nuclei, mainly projecting to the thalamus and subcortical …

Involvement of the default mode network (DMN) in cognitive symptoms of Parkinson's
disease (PD) has been reported by resting‐state functional MRI (rsfMRI) studies. However …

The limbic system describes a complex of brain structures central for memory, learning, as
well as goal directed and emotional behavior. In addition to pathological studies, recent …

Background Previous research has described distinct subtypes of Alzheimer's disease (AD)
based on the differences in regional patterns of brain atrophy on MRI. We conducted a data …

Cognitive decline in Parkinson's disease is related to cholinergic system degeneration,
which can be assessed in vivo using structural MRI markers of basal forebrain volume and …

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Patients who have dementia with Lewy bodies and Alzheimer's disease show early
degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter …